[go: up one dir, main page]

BRPI0502228A - forma cristalina alfa de ranelato de estrÈncio, processo para sua preparação, e composições farmacêuticas que a contêm - Google Patents

forma cristalina alfa de ranelato de estrÈncio, processo para sua preparação, e composições farmacêuticas que a contêm

Info

Publication number
BRPI0502228A
BRPI0502228A BRPI0502228-2A BRPI0502228A BRPI0502228A BR PI0502228 A BRPI0502228 A BR PI0502228A BR PI0502228 A BRPI0502228 A BR PI0502228A BR PI0502228 A BRPI0502228 A BR PI0502228A
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
strontium ranelate
crystalline form
Prior art date
Application number
BRPI0502228-2A
Other languages
English (en)
Inventor
Stephane Horvath
Isabelle Demuynck
Gerard Damen
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34942420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0502228(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of BRPI0502228A publication Critical patent/BRPI0502228A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Fodder In General (AREA)

Abstract

"FORMA CRISTALINA ALFA DE RANELATO DE ESTRONCIO, PROCESSO PARA SUA PREPARAçãO, E COMPOSIçõES FARMACêUTICAS QUE A CONTêM". A presente invenção refere-se à forma cristalina alfa de ranelato de estróncio, da fórmula (I): caracterizada por seu diagrama de difração de raios X de pó, e por um teor de água entre 22 e 24%.
BRPI0502228-2A 2004-09-30 2005-06-17 forma cristalina alfa de ranelato de estrÈncio, processo para sua preparação, e composições farmacêuticas que a contêm BRPI0502228A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0410335A FR2875807B1 (fr) 2004-09-30 2004-09-30 Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
BRPI0502228A true BRPI0502228A (pt) 2006-05-09

Family

ID=34942420

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0502228-2A BRPI0502228A (pt) 2004-09-30 2005-06-17 forma cristalina alfa de ranelato de estrÈncio, processo para sua preparação, e composições farmacêuticas que a contêm

Country Status (42)

Country Link
US (2) US7459568B2 (pt)
EP (2) EP1642897B9 (pt)
JP (2) JP2006104184A (pt)
KR (1) KR100816590B1 (pt)
CN (1) CN100391956C (pt)
AP (1) AP1930A (pt)
AR (1) AR049395A1 (pt)
AT (1) ATE411308T1 (pt)
AU (1) AU2005202718B2 (pt)
BR (1) BRPI0502228A (pt)
CA (1) CA2508824C (pt)
CO (1) CO5710195A1 (pt)
CR (1) CR7876A (pt)
CY (1) CY1108797T1 (pt)
DE (1) DE602005010359D1 (pt)
DK (1) DK1642897T3 (pt)
EA (1) EA008474B1 (pt)
EC (1) ECSP055859A (pt)
ES (1) ES2314593T3 (pt)
FR (1) FR2875807B1 (pt)
GE (1) GEP20074106B (pt)
GT (1) GT200500130A (pt)
HK (1) HK1086260A1 (pt)
HR (1) HRP20080652T3 (pt)
IL (1) IL169237A (pt)
MA (1) MA27815A1 (pt)
MX (1) MXPA05006407A (pt)
NO (1) NO333948B1 (pt)
NZ (1) NZ540802A (pt)
OA (1) OA13013A (pt)
PA (1) PA8638201A1 (pt)
PE (1) PE20060364A1 (pt)
PL (1) PL1642897T3 (pt)
PT (1) PT1642897E (pt)
RS (1) RS51110B (pt)
SA (1) SA05260168B1 (pt)
SG (1) SG121035A1 (pt)
SI (1) SI1642897T1 (pt)
TW (1) TWI367881B (pt)
UA (1) UA80008C2 (pt)
WO (1) WO2006035122A1 (pt)
ZA (1) ZA200504937B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
CN101206208B (zh) * 2006-12-19 2011-08-10 北京德众万全药物技术开发有限公司 一种用hplc法分析雷尼酸锶原料及其制剂的方法
CN102227419A (zh) * 2008-09-29 2011-10-26 拉蒂奥法姆有限责任公司 无水和水合形式的雷奈酸锶
IT1398542B1 (it) * 2010-03-05 2013-03-01 Chemelectiva S R L Processo per la preparazione di un polimorfo
CN102241663B (zh) * 2010-05-10 2013-02-13 山东方明药业集团股份有限公司 一种雷奈酸锶八水合物的制备方法
WO2012143932A1 (en) * 2011-04-21 2012-10-26 Shilpa Medicare Limited Crystalline strontium ranelate form-s
CZ2011320A3 (cs) 2011-05-30 2012-12-12 Zentiva, K.S. Stabilní krystalická forma X stroncium ranelátu
EP2530068A1 (en) 2011-05-31 2012-12-05 Lacer, S.A. New strontium salts, synthesis and use thereof in the treatment of osteoporosis
WO2013013003A1 (en) 2011-07-21 2013-01-24 Emory University Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation
CN102503931A (zh) * 2011-09-20 2012-06-20 浙江华海药业股份有限公司 一种雷尼酸锶晶形h的制备方法
WO2013113319A1 (en) * 2012-01-31 2013-08-08 Pharmathen S.A. Process for the preparation of strontium ranelate, intermediate or hydrates thereof
EP2641905A1 (en) 2012-03-23 2013-09-25 Urquima S.A. Solid forms of strontium ranelate and processes for their preparation
US8569514B1 (en) 2012-05-17 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of strontium ranelate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651497B1 (fr) * 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
PL181304B1 (pl) 1994-07-22 2001-07-31 Lilly Co Eli Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
DE19642451A1 (de) 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
US7227033B2 (en) * 2002-01-09 2007-06-05 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
EP1992629A1 (en) * 2001-10-03 2008-11-19 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and forms thereof
WO2004012739A1 (en) * 2002-08-06 2004-02-12 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
FR2844797B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844796A1 (fr) 2002-09-24 2004-03-26 Servier Lab Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844795B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
JP2006104184A (ja) 2006-04-20
UA80008C2 (uk) 2007-08-10
AU2005202718B2 (en) 2010-09-16
IL169237A (en) 2010-12-30
CA2508824A1 (fr) 2006-03-30
NO20052998L (no) 2006-03-31
PT1642897E (pt) 2008-11-27
DE602005010359D1 (de) 2008-11-27
ATE411308T1 (de) 2008-10-15
TW200610758A (en) 2006-04-01
EP1944302A1 (fr) 2008-07-16
OA13013A (fr) 2006-11-10
AU2005202718A1 (en) 2006-04-13
CY1108797T1 (el) 2014-04-09
TWI367881B (en) 2012-07-11
NO20052998D0 (no) 2005-06-17
ECSP055859A (es) 2006-09-18
CA2508824C (fr) 2009-03-24
US20080312314A1 (en) 2008-12-18
CR7876A (es) 2007-12-10
WO2006035122A1 (fr) 2006-04-06
EA008474B1 (ru) 2007-06-29
AP2005003323A0 (en) 2005-06-30
KR100816590B1 (ko) 2008-03-24
NO333948B1 (no) 2013-10-28
RS51110B (sr) 2010-10-31
MXPA05006407A (es) 2006-04-05
SI1642897T1 (sl) 2009-02-28
AP1930A (en) 2008-12-15
GT200500130A (es) 2005-12-20
EP1642897A1 (fr) 2006-04-05
CN100391956C (zh) 2008-06-04
EP1642897B1 (fr) 2008-10-15
FR2875807A1 (fr) 2006-03-31
SG121035A1 (en) 2006-04-26
PA8638201A1 (es) 2006-05-16
PE20060364A1 (es) 2006-06-17
PL1642897T3 (pl) 2009-04-30
AR049395A1 (es) 2006-07-26
HK1086260A1 (en) 2006-09-15
CN1754878A (zh) 2006-04-05
CO5710195A1 (es) 2006-12-29
EA200500842A1 (ru) 2006-04-28
MA27815A1 (fr) 2006-04-03
SA05260168B1 (ar) 2009-02-25
ES2314593T3 (es) 2009-03-16
HRP20080652T3 (en) 2009-01-31
JP2010132669A (ja) 2010-06-17
ZA200504937B (en) 2006-04-26
KR20060049966A (ko) 2006-05-19
NZ540802A (en) 2006-11-30
GEP20074106B (en) 2007-05-10
US7459568B2 (en) 2008-12-02
US7745482B2 (en) 2010-06-29
US20060069271A1 (en) 2006-03-30
DK1642897T3 (da) 2009-01-26
FR2875807B1 (fr) 2006-11-17
EP1642897B9 (fr) 2009-08-12

Similar Documents

Publication Publication Date Title
BRPI0603059A (pt) forma cristalina v de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0603043A (pt) forma cristalina iv de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0502228A (pt) forma cristalina alfa de ranelato de estrÈncio, processo para sua preparação, e composições farmacêuticas que a contêm
BRPI0600795A (pt) forma betad-cristalina de cloridrato de ivabradina, um processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
BRPI0600796A (pt) forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
AR053147A1 (es) Forma cristalina del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen
BRPI0603074A (pt) forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0500393A (pt) Processo para a sìntese e forma cristalina de agomelatina e composições farmacêuticas contendo-a
BRPI0604253A (pt) forma deltad-cristalina de cloridrato de ivabradina, um processo para sua preparação e composições farmacêuticas contendo-as
BRPI0600696A (pt) forma gamad-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
ECSP088859A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
ECSP066915A (es) Forma cristalina delta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmaceuticas que la contienen
UA84208C2 (en) Tetraazabenzo(e)azulene derivatives and analogs thereof
BRPI0409109A (pt) novos compostos
BRPI0708278B8 (pt) forma cristalina "a" do sal de arginina de perindopril, seu uso, processo para sua preparação e composição farmacêutica
BR0112244A (pt) Forma cristalina beta do sal de terc-butilamina do perindopril, respectivo processo de preparação e composições farmacêuticas que a contêm
BR112021023927A2 (pt) Composto, e, composição farmacêutica
BRPI0801239A2 (pt) uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
MY157492A (en) Pharmaceutical composition 271
BRPI0602206B8 (pt) forma polimórfica a de dexcetoprofeno trometamol e composições que a contém
UY28969A1 (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
BRPI0513566A (pt) composição farmacêutica compreendendo gabapentina
UY29855A1 (es) Forma cristalina delta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
Lovschall et al. Novel nanohybrid MTA compositions: a new direction in regeneration of dental hard tissue
CU20060195A7 (es) Forma cristalina delta-d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmacéuticas que lo contienen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]